Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Probe By U.S. Expands To Insulin Manufacturing

This article was originally published in The Pink Sheet Daily

Executive Summary

Massachusetts U.S. Attorney’s office, which is also investigating firm’s marketing, now subpoenas Novo Nordisk for documents relating to potential issues at its plant in Kalundborg, Denmark.

You may also be interested in...



Emerging Markets Earnings: Novo Nordisk Sticks To The Plan

Novo Nordisk has a plan in emerging markets and is sticking to it, as senior executives detailed in the third quarter earnings call.

Kickback Suit Against Novartis Can Proceed, Judge Says

Federal judge rules against Novartis’ motion to dismiss a whistleblower suit alleging violations of the anti-kickback statute and the False Claims Act, saying the government’s evidence is specific enough to proceed.

Under DOJ’s Microscope: Teva Is Latest Company To Face Government Probe

AstraZeneca, Merck, Novartis and Sanofi are also under investigation for potential health care fraud.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel